Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNMT | O43148 | 2/20 | 0.32 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.30 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.30 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL753363 | 0.87 | POLB (0.34) | — | |
| SCHEMBL753549 | 0.86 | PRKAG1 (0.31) | PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL733412 | 0.82 | RNMT (0.30) | RNMT | |
| SCHEMBL29674590 | 0.81 | TYMP (0.39) | PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL2054229 | 0.81 | TYMP (0.39) | PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL15786367 | 0.81 | TYMP (0.39) | PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL29449394 | 0.81 | TYMP (0.39) | PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL9539565 | 0.80 | TYMP (0.38) | PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL24354782 | 0.79 | TYMP (0.38) | PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL733920 | 0.79 | KDM4E (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138330-B2 | Solid phase synthesis via deblocking immobilized nucleoside, then coupling acyl protected nucleoside phosphoramidite | SIGMA-ALDRICH CO. LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138330-B2 | Solid phase synthesis via deblocking immobilized nucleoside, then coupling acyl protected nucleoside phosphoramidite | SIGMA-ALDRICH CO. LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-20080064867-A1 | PROCESS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES | SIGMA ALDRICH COMPANY (US) | 2008-03-13 | — | — | US | disclosed |
| US-20080064867-A1 | PROCESS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES | SIGMA ALDRICH COMPANY (US) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064867-A1 | PROCESS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES | RNGTT, DUT, ADAR | RNMT 20/4885PRKAG1 1311/4885PRKAA1 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.